Drug Trial Radar · NCT00705679
Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women
Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,029
Actual
Start
Aug 2009
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Sponsor type
- NIH
- Collaborators
- Microbicide Trials Network
- First posted
- Jun 26, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A new approach to HIV prevention currently being studied includes the use of microbicides, substances that kill microbes. Tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) are oral, FDA-approved, anti-HIV drugs, and tenofovir gel is an experimental microbicide. The purpose of this study is to determine the safety and effectiveness of daily tenofovir 1% gel compared to a vaginal placebo gel, and the safety and effectiveness of oral TDF and oral FTC/TDF compared to an oral placebo in preventing HIV infection among women at risk for sexually transmitted infections.
Conditions
- HIV Infections
Interventions
Emtricitabine/tenofovir disoproxil fumarateDrug
200 mg/300 mg tablet
Emtricitabine/tenofovir disoproxil fumarate placeboDrug
placebo tablet
Tenofovir disoproxil fumarateDrug
300 mg tablet
Tenofovir disoproxil fumarate placeboDrug
placebo tablet
Tenofovir 1% vaginal gelDrug
1 gm/100 ml of 1% gel
Tenofovir placeboDrug
placebo gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel ArmsTime frame: For up to 30 months of follow-up
- Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel ArmsTime frame: For up to 30 months of follow-up
- Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel ArmsTime frame: For up to 30 months of follow-up
- Person-years of Follow-up of Oral TDF and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
- Number of HIV-1 Infections of Oral TDF and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
- Incidence Rate of HIV-1 Infections of Oral TDF and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
- Person-years of Follow-up of Oral TDF-FTC and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
- Number of HIV-1 Infections of Oral TDF-FTC and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
- Incidence Rate of HIV-1 Infections of Oral TDF-FTC and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
- Extended Safety of Daily Tenofovir 1% Gel, Oral TDF, and Oral FTC/TDF in Women at Risk for Sexually Transmitted HIV Infection Based on Occurrence of Grade 2, 3, and 4 Adverse EventsTime frame: Throughout study, up to 2.5 years
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
CAPRISA Aurum CRS
Klerksdorp, South Africa
Wits Reproductive Health and HIV Institute CRS (WRHI CRS)
Johannesburg, Gauteng, South Africa
Soweto MTN CRS
Johannesburg, Gauteng, South Africa
Overport CRS
Asherville, KwaZulu-Natal, South Africa
Chatsworth CRS
Chatsworth, KwaZulu-Natal, South Africa
eThekwini CRS
Durban, KwaZulu-Natal, South Africa
Umkomaas CRS
eMkhomazi, KwaZulu-Natal, South Africa
Tongaat CRS
Tongaat, KwaZulu-Natal, South Africa
Verulam CRS
Verulam, KwaZulu-Natal, South Africa
Botha's Hill CRS
Westville, KwaZulu-Natal, South Africa
Isipingo CRS
Westville, KwaZulu-Natal, South Africa
MU-JHU Research Collaboration CRS
Kampala, Uganda
Seke South CRS
Chitungwiza, Zimbabwe
Zengeza CRS
Chitungwiza, Zimbabwe
Spilhaus CRS
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.